u/bossman-CT

HINGHAM, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced it will be hosting an analysts and investors conference call on Monday, May 18^(th), at 3:00pm ET, to review the recent progress of the Full Market Release (FMR) of the LIBERTY System and to ensure the investing public is correctly and fully informed on company and product information that was recently misrepresented by a recent unaffiliated third-party article.

Harel Gadot, the Company’s Chairman, CEO & President, will be joined by other senior executives. Additionally, Dr. Charles Briggs, a vascular surgeon and one of the users of the LIBERTY System at Tampa General Hospital, will share his own experience with the LIBERTY System. Dr. Briggs will also address certain inaccuracies attributed to him, which were recently made by an unaffiliated third party in their article. Dr. Zachary L. Bercu, an interventional radiologist with Emory Healthcare and professor in the Division of Interventional Radiology and Image-Guided Medicine at Emory University School of Medicine, and the first user of the LIBERTY System, will also join and discuss the experience of utilizing the LIBERTY System in the everyday practice of their interventional radiology department.

To access the live webcast of the conference call, please go to the investor relations section of Microbot Medical’s website at http://www.microbotmedical.com. Participants may also register via teleconference at: https://register-conf.media-server.com/register/BI3230e15aa058488caa9b629910cade7c. Once registration is completed, participants will be provided with a dial-in number containing a personalized PIN to access the call. Participants are requested to register a day in advance or at a minimum 15 minutes before the start of the call.

Microbot Medical says its LIBERTY robotic system has officially moved from limited release into full commercial operations, and the early ramp looks strong. The company reports that mid‑Q2 revenue has already surpassed all of Q1 as more hospitals begin using the system and existing sites increase procedure volume.

LIBERTY is now commercially active in six states — Georgia, Florida, New York, Michigan, Massachusetts, and North Carolina — with Boston becoming the first city to have multiple active accounts. According to the company, customer sites more than doubled once the limited rollout ended, and two of the three pivotal trial locations have already converted into paying commercial users.

They’re also highlighting a string of early clinical wins across different specialties, including robotic PAE for BPH, robotic GAE for knee pain, and robotic Y‑90 mapping and treatment for liver cancer. The company is framing these as proof that LIBERTY isn’t just novel tech — it’s being used in real procedures with real demand behind it!

Exciting stuff!

_____________

EDIT: You'll notice the price is down 20% this morning. White Diamond Research released a hit piece 30 minutes after the good news and has a bot on MBOT_Stock subreddit, spreading fud. If you want a fantastic buying opportunity, now is the time. No negative news has been released since FDA approval. The price has come down from stock dilution which is normal for a small cap biotech company. This stock will FLY once retail realizes this was a bullshit fud/hit piece

Microbot Medical says its LIBERTY robotic system has officially moved from limited release into full commercial operations, and the early ramp looks strong. The company reports that mid‑Q2 revenue has already surpassed all of Q1 as more hospitals begin using the system and existing sites increase procedure volume.

LIBERTY is now commercially active in six states — Georgia, Florida, New York, Michigan, Massachusetts, and North Carolina — with Boston becoming the first city to have multiple active accounts. According to the company, customer sites more than doubled once the limited rollout ended, and two of the three pivotal trial locations have already converted into paying commercial users.

They’re also highlighting a string of early clinical wins across different specialties, including robotic PAE for BPH, robotic GAE for knee pain, and robotic Y‑90 mapping and treatment for liver cancer. The company is framing these as proof that LIBERTY isn’t just novel tech — it’s being used in real procedures with real demand behind it!

Exciting stuff!

---

EDIT: /u/SuspiciousMud6208 is a bot. Notice it's a new account and are unable to quote a single thing from the article they are posting. Classic fud/hit piece from White Diamond Research (a short biased firm) who likely created the bot account and it's working. Don't get spooked. HOLD and BUY. The price has come down due to dilution of shares since FDA approval. We've had positive news since then, MBOT has secured hospital networks in multiple states. I'm not worried in the slightest

Capital One opened a case, and then charged back the flight.. then a couple days later, Spirit refunded the flight. I contacted Capital One again and let them know and they can close the case, but I still have the chargeback + the Spirit refund..

What should I do? Spirit doesn't have customer support, how does this all work? Anyone else run into this before with a company that went out of business?